13 recruiting, 11 completed, 8 unknown, 3 not yet recruiting. 11 Phase 2, 9 Phase 3, 7 Not applicable, 1 Phase 1.
Follow Radiotherapy, Adjuvant: new trials by email Literature Review of Radiotherapy, Adjuvant trials Research Report on Radiotherapy, Adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery Adjuvant Radiotherapy, tamoxifen - Ductal Carcinoma In Situ, DCIS | Phase 3 | Recruiting | Fudan University | 636 | 2026-07-01 | 2026-08-13 |
| De-escalation of RNI in Breast Cancer Patients With pN0 After Neoadjuvant Therapy Adjuvant Radiotherapy - Breast Cancer | Not applicable | Not yet recruiting | Aya Ahmed Sayed | 100 | 2026-06-01 | 2026-07-24 |
| Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study Upfront Breast Surgery, Adjuvant Radiotherapy, Endocrine Therapy - Lobular Breast Carcinoma | Recruiting | Istituto Oncologico Veneto IRCCS | 250 | 2026-05-01 | 2026-09-02 | |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 42 | 2026-04-20 | 2026-06-01 |
| Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy - Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma | Not yet recruiting | Zhujiang Hospital | 85 | 2026-04-01 | 2026-03-09 | |
| Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant and Adjuvant Becotatug Vedotin, Neoadjuvant and Adjuvant Immunotherapy, Surgery - Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | Ming-Yuan Chen | 430 | 2026-02-06 | 2026-04-13 |
| Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant and Adjuvant Immunotherapy, Low-dose radiotherapy, Surgery - Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Rui You | 22 | 2025-12-15 | 2026-09-01 |
| EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial Adjuvant Radiotherapy - Breast Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 300 | 2025-07-17 | 2026-05-15 |
| Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy - Breast Cancer | Phase 2 | Recruiting | Xijing Hospital | 27 | 2025-06-05 | 2026-08-14 |
| Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence Adjuvant radiotherapy - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 3 | Recruiting | Centre Leon Berard | 266 | 2025-02-21 | 2026-04-24 |
| Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma Pembrolizumab, Ivonescimab, Surgery - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC | Phase 2 | Not yet recruiting | Fudan University | 80 | 2025-02-10 | 2025-02-07 |
| Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection Adjuvant Radiotherapy, R0 resection - Radiotherapy, Adjuvant, Phyllodes Breast Tumor | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 480 | 2024-12-30 | 2025-01-17 | |
| RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer adjuvant radiotherapy - Thyroid Cancer | Recruiting | Fudan University | 80 | 2024-07-02 | 2026-02-27 | |
| Neoadjuvant Radiotherapy for Breast Cancer Neoadjuvant radiotherapy, adjuvant radiotherapy - Neoadjuvant Radiotherapy, Breast Cancer | Not applicable | Unknown | Changhai Hospital | 60 | 2024-04-01 | 2024-03-15 |
| Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy Adjuvant radiotherapy, Observation - Adjuvant Radiotherapy | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 146 | 2024-03-01 | 2024-07-16 |
| Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management Surgical wide local excision, Cavity shaving, Excision margin surgical clearance - Pleomorphic Lobular Breast Carcinoma in Situ, Breast Florid Lobular Carcinoma in Situ | Completed | Istituto Oncologico Veneto IRCCS | 1063 | 2023-10-15 | 2026-04-01 | |
| Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy - Urinary Bladder Neoplasms | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 65 | 2023-02-01 | 2022-12-28 |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation - Endometrial Cancer | Phase 2 | Recruiting | Canadian Cancer Trials Group | 393 | 2022-12-19 | 2026-10-14 |
| Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy No adjuvant therapy, Adjuvant radiotherapy - Cervical Cancer | Phase 3 | Recruiting | The Central and Eastern European Gynecologic Oncology Group | 514 | 2022-06-10 | 2023-09-07 |
| Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection Adjuvant Radiotherapy - Esophageal Cancer | Unknown | Chinese Academy of Medical Sciences | 3591 | 2022-04-23 | 2022-07-15 |
Showing 20 of 38. Sign in to see all of them.
Breast Neoplasms (6) · Esophageal Neoplasms (4) · Head and Neck Neoplasms (3) · Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Squamous Cell (2) · Phyllodes Tumor (2) · Prostatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Lobular (1) · Endometrial Neoplasms (1) · Laryngeal Diseases (1) · Laryngeal Neoplasms (1) · Liver Neoplasms (1)
Fudan University (4) · Chinese Academy of Medical Sciences (2) · Istituto Oncologico Veneto IRCCS (2) · Zhejiang Cancer Hospital (2) · Aya Ahmed Sayed (1) · Beijing Stomatological Hospital, Capital Medical University (1) · Cairo University (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Changhai Hospital (1) · Dartmouth-Hitchcock Medical Center (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Helsinki University Central Hospital (1) · Humanitas Clinical and Research Center (1) · M.D. Anderson Cancer Center (1)
China (19) · Italy (4) · United States (4) · Australia (2) · Egypt (2) · France (2) · Germany (2) · New Zealand (2) · Canada (1) · Czechia (1) · India (1) · Netherlands (1) · Norway (1) · United Kingdom (1)
Andrew Kneebone (1) · Christopher W. Ryan, MD (1) · Chunyan Chen, MD, PhD (1) · David Cibula, prof. (1) · Davide Franceschini (1) · Dian-can Wang, M.D. (1) · Francesco Milardi, MD (1) · Fuxiang Zhou, M.D. (1) · Jessica McAlpine (1) · Jinhai Fan, MD (1) · Joseph Sacco, MBChB (1) · Kathy Han (1) · Marco Klinger (1) · Maria Pearse, MBChB (1) · Massimo Ferrucci, MD PhD (1)
PMID 14673047, PMID 1612951, PMID 16794899, PMID 19424757, PMID 20421764, PMID 20626450, PMID 25164541, PMID 26530541, PMID 29188298, PMID 30926067, PMID 33002437, PMID 34097307, PMID 35883131, PMID 36100282, PMID 36239788, PMID 41287448
2017 (1), P30CA023108 (1), P30CA069533 (1)